Biotech RadarJobs updated

COMPANY

iCell Gene Therapeutics

icellgene.com ↗

Clinical Phase 2

Keywords: oncology acute myeloid leukemia immunology lymphoma autoimmune diseases T-cell Acute Lymphoblastic Leukemia T-cell Non-Hodgkin Lymphoma Hematologic Malignancy Myelodysplastic Syndromes Myeloproliferative Neoplasm Chronic Myeloid Leukemia B Cell Lymphoma B Cell Leukemia Systemic Lupus Erythematosus Lupus Nephritis Inflammatory Myopathy Inflammatory Bowel Diseases Multiple Myeloma in Relapse Refractory Multiple Myeloma Refractory Immune Cytopenia Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) Relapsed and/or Refractory Acute Myeloid Leukemia High Risk Hematologic Malignancies High Risk Hematologic Malignancies Relapsed/Refractory T-ALL/Lymphoma T-cell Acute Lymphoblastic Lymphoma T Cell Lymphoma in Relapse Refractory T-Cell Lymphoma Multiple Myeloma BCMA-CD19 cCAR T cells ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T anti-CD33 CAR T cells CD7CAR T cells CD7 CAR T cells CD4 CAR T cells CLL1-CD33 cCAR T cells anti-CD5 CAR T cells CD123-CD33 cCAR T cells CD19 CARvac T cells BCMA-CS1 cCAR T cells CD20-CD19 cCAR T cells

Profile checked Oct 10, 2026

17Trials (company is sponsor)

Timeline

  1. Trial start II: A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis source ↗
  2. Trial start Phase 1: Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia source ↗
  3. Trial start Phase 1/Phase 2: BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) source ↗
  4. Trial start Phase 1: BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy source ↗
  5. Trial start Phase 1: BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases source ↗
  6. Trial start Phase 1: Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia source ↗
  7. Trial start Phase 1: CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma source ↗
  8. Trial start Phase 1: BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) source ↗
  9. Trial start Phase 1: Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances source ↗
  10. Trial start Phase 1: Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies source ↗
  11. Trial start Phase 1: CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies source ↗
  12. Trial start Phase 1: BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma source ↗
  13. Trial start Early phase 1: BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma source ↗
  14. Trial start Early phase 1: CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies source ↗
  15. Trial start Early phase 1: CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies source ↗
  16. Trial start Early phase 1: CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies source ↗
  17. Trial start Early phase 1: CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 17

RecordTitlePhaseStatusStartPrimary completion
NCT07328581A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus NephritisIIRecruiting2026-092028-12 (estimated)
NCT07715136BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory MyopathyPhase 1RecruitingMar 20, 2025Dec 31, 2027 (estimated)
NCT07668557Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPhase 1RecruitingJun 10, 2026Jul 4, 2028 (estimated)
NCT07544160BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)Phase 1/Phase 2Not yet recruitingApr 7, 2026Apr 7, 2028 (estimated)
NCT04162353BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid LymphomaPhase 1RecruitingJul 1, 20192026-07 (estimated)
NCT06787989BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune DiseasesPhase 1RecruitingAug 31, 20242026-08 (estimated)
NCT05474885BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)Phase 1Unknown status (ClinicalTrials.gov)Apr 1, 2022Apr 30, 2025 (estimated)
NCT05445765Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid LeukemiaPhase 1Unknown status (ClinicalTrials.gov)Jul 1, 2022Jun 30, 2024 (estimated)
NCT05212584CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ LymphomaPhase 1Unknown status (ClinicalTrials.gov)Jul 1, 2022Jun 30, 2024 (estimated)
NCT04934774Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell MalignancesPhase 1Unknown status (ClinicalTrials.gov)Dec 1, 2020Jun 1, 2023 (estimated)
NCT04162340CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell MalignanciesPhase 1Unknown status (ClinicalTrials.gov)Jul 11, 20192021-10 (estimated)
NCT03795779CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesEarly phase 1Unknown status (ClinicalTrials.gov)Mar 1, 2018Sep 30, 2022 (estimated)
NCT04594135Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell MalignanciesPhase 1Unknown status (ClinicalTrials.gov)Dec 1, 2020Nov 30, 2023 (estimated)
NCT04156256CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesEarly phase 1Unknown status (ClinicalTrials.gov)Mar 1, 2018Sep 30, 2020 (estimated)
NCT04156243CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell MalignanciesEarly phase 1Unknown status (ClinicalTrials.gov)Feb 1, 2018Feb 28, 2020 (estimated)
NCT04156269BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple MyelomaEarly phase 1Unknown status (ClinicalTrials.gov)Aug 31, 2018Sep 1, 2021 (estimated)
NCT04156178CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell MalignanciesEarly phase 1Unknown status (ClinicalTrials.gov)Aug 1, 2018Sep 30, 2020 (estimated)
Feedback